News

Ozoralizumab includes two nanobodies targeting TNFa, which are linked to a nanobody that binds to human serum albumin, extending the drug’s half-life and improving its distribution to inflamed

In addition to this non-contingent license payment of $120.0 million, as previously announced, FibroGen received a $15.0 million milestone payment from AstraZeneca during the second quarter of 2015

The collaboration is designed to identify combination regimens that provide synergies in efficacy and durability in patients with metastatic cutaneous and uveal melanomas. IMCgp100 is Immunocore’s lead T

This single ascending dose trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-43742 in healthy human volunteers, with results expected in the second half of 2015.

BioBlast is currently conducting a Phase 2 study in patients suffering from SCA3 in Israel. Cabaletta is a chemical chaperone that has been shown to prevent pathological aggregation

The acquisition further enhances BSN medical’s comprehensive product portfolio for the management of lymphatic and venous disorders under the JOBST and Elvarex brands. "This acquisition benefits BSN and

Pursuant to the amendment, Sandoz will increase its commercial investment in KERYDIN in 2015, and Anacor will contribute $20 million to Sandoz, primarily focused on consumer-directed commercialization activities.

Dextromethorphan is designed to treat cough due to minor throat and bronchial irritation. As part of the deal, Tris will be responsible for manufacturing and regulatory activities, while

Trevyent is SteadyMed’s lead drug product candidate currently under development stage that combines its PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat PAH. As part of